The Zhitong Finance App learned that on September 3, the CDE official website showed that the marketing application for Roche (RHHBY.US) vamicibimab injection was accepted for the treatment of uveal inflammatory macular edema (UME). Previously, the application had been included by the CDE in the priority review and approval process.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.